Tukysa is a kinase inhibitor recommended in combination with Trastuzumab and Capecitabine for treating adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases who received one or more prior anti-HER2-based regimens in the metastatic setting and in combination with Trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed succeeding treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Tucatinib: Treatment for metastatic HER2-positive breast cancer
Breast cancer (HER2-positive) happens when the cancer cells have higher than normal levels of a protein called human epidermal growth factor receptor 2 (HER2). This protein is also in the breast tissue of people who don’t have breast cancer. HER2 helps breast cells grow and multiply. It also helps them repair damage.
But sometimes, a cell’s gene mistakes cause the body to make too much HER2. This can cause breast cells to grow faster than usual. That can lead to cancer.
About 20% of breast cancers are HER2-positive. They usually grow quicker than other types of cancer.
Metastatic HER2-positive breast cancer has spread beyond the breast to other body parts.
The drug, Tucatinib, is a tyrosine kinase inhibitor of HER2. In clinical trials, Tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed antitumor activity in HER2-expressing tumor cells. In vivo, Tucatinib inhibited the growth of HER2-expressing tumors. The Tucatinib and Trastuzumab combination showed increased antitumor activity in vitro and in vivo compared to either drug alone.
Healthcare professionals Tucatinib dosage is 300 mg taken orally twice daily in combination with Trastuzumab and capecitabine until disease progression or unacceptable toxicity.
Tukysa: Treatment of metastatic colorectal cancer
The Colorectal cancer starts in the colon or rectum. This kind of cancer is staged from stage 0, very early, to stage 4, metastatic colorectal cancer.
Colorectal cancer which has been metastasized, is called Metastatic colorectal cancer, which has spread to regional or distant sites, such as other organs or lymph nodes.
Though cancer can spread to any other body part, colorectal cancer most often spreads to the liver, lung, or peritoneum, according to the National Cancer Institute.
The drug, Tucatinib, is a tyrosine kinase inhibitor of HER2. In clinical studies, Tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed antitumor activity in HER2-expressing tumor cells. In vivo, Tucatinib inhibited the growth of HER2-expressing tumors. The Tucatinib and Trastuzumab combination showed increased antitumor activity in vitro and in vivo compared to either drug alone.
According to the FDA, the recommended dosage of Tukysa tablets is 300 mg, taken orally twice daily in combination with Trastuzumab until disease progression or unacceptable toxicity.
Tucatinib is sold under the brand name Tukysa, a kinase inhibitor with standard strengths of 50 mg and 150 mg. Tukysa price in India is reasonable, and one can easily purchase this medicine from certified pharmaceutical suppliers like Indian Pharma Network. To know more about this medicine, call us at 18008891064.
